Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
The burden of decisional uncertainty in the treatment of status epilepticus
Epilepsia ( IF 6.6 ) Pub Date : 2020-09-22 , DOI: 10.1111/epi.16646 Iván Sánchez Fernández 1, 2 , Marina Gaínza-Lein 1, 3, 4 , Cristina Barcia Aguilar 1, 5 , Marta Amengual-Gual 1, 6 , Tobias Loddenkemper 1
Epilepsia ( IF 6.6 ) Pub Date : 2020-09-22 , DOI: 10.1111/epi.16646 Iván Sánchez Fernández 1, 2 , Marina Gaínza-Lein 1, 3, 4 , Cristina Barcia Aguilar 1, 5 , Marta Amengual-Gual 1, 6 , Tobias Loddenkemper 1
Affiliation
Treatments for convulsive status epilepticus (SE) have a wide range of effectiveness. The estimated effectiveness of non‐intravenous benzodiazepines (non‐IV BZDs) ranges from approximately 70% to 90% and the estimated effectiveness of non‐benzodiazepine antiseizure medications (non‐BZD ASMs) ranges from approximately 50% to 80%. This study aimed to quantify the clinical and economic burden of decisional uncertainty in the treatment of SE.
中文翻译：
癫痫持续状态治疗中决策不确定性的负担
惊厥性癫痫持续状态 (SE) 的治疗具有广泛的有效性。非静脉内苯二氮卓类药物 (non-IV BZDs) 的估计有效性范围约为 70% 至 90%，非苯二氮卓类抗癫痫药物 (non-BZD ASMs) 的估计有效性范围约为 50% 至 80%。本研究旨在量化 SE 治疗中决策不确定性的临床和经济负担。
更新日期：2020-09-22
中文翻译：
癫痫持续状态治疗中决策不确定性的负担
惊厥性癫痫持续状态 (SE) 的治疗具有广泛的有效性。非静脉内苯二氮卓类药物 (non-IV BZDs) 的估计有效性范围约为 70% 至 90%，非苯二氮卓类抗癫痫药物 (non-BZD ASMs) 的估计有效性范围约为 50% 至 80%。本研究旨在量化 SE 治疗中决策不确定性的临床和经济负担。
京公网安备 11010802027423号